quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:12:42·56d
SECFiling
Xenon Pharmaceuticals Inc. logo

SEC Form 10-K filed by Xenon Pharmaceuticals Inc.

XENE· Xenon Pharmaceuticals Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • XENE
    Xenon Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Feb 24UpdateWolfe Research$60.00
  • Sep 3UpdateWells Fargo$48.00
  • May 7UpdateChardan Capital Markets$55.00
  • Feb 11UpdateDeutsche Bank$67.00
  • Oct 10UpdateRaymond James$50.00
  • Oct 1UpdateH.C. Wainwright$53.00

Related

  • SEC1d
    SEC Form DEFA14A filed by Xenon Pharmaceuticals Inc.
  • SEC1d
    SEC Form DEF 14A filed by Xenon Pharmaceuticals Inc.
  • PR8d
    Xenon to Present at Upcoming Investor Conferences
  • SEC10d
    SEC Form S-8 filed by Xenon Pharmaceuticals Inc.
  • SEC10d
    Xenon Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
  • PR16d
    Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting
  • INSIDER41d
    Chief Medical Officer Kenney Christopher John converted options into 3,750 shares and sold $77,867 worth of shares (1,410 units at $55.23), increasing direct ownership by 49% to 7,069 units (SEC Form 4)
  • INSIDER41d
    Chief Legal Officer Difabio Andrea sold $74,112 worth of shares (1,342 units at $55.22) and converted options into 3,750 shares, increasing direct ownership by 49% to 7,301 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022